Title | Relative Incidence of Seizures and Myoclonus in Alzheimer's Disease, Dementia with Lewy Bodies, and Frontotemporal Dementia. |
Publication Type | Journal Article |
Year of Publication | 2017 |
Authors | Beagle, AJ, Darwish, SM, Ranasinghe, KG, La, AL, Karageorgiou, E, Vossel, KA |
Journal | J Alzheimers Dis |
Volume | 60 |
Issue | 1 |
Pagination | 211-223 |
Date Published | 2017 |
ISSN | 1875-8908 |
Abstract | BACKGROUND: Patients with Alzheimer's disease (AD) are more prone to seizures and myoclonus, but relative risk of these symptoms among other dementia types is unknown. OBJECTIVE: To determine incidence of seizures and myoclonus in the three most common neurodegenerative dementias: AD, dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD). METHODS: Our institution's medical records were reviewed for new-onset unprovoked seizures and myoclonus in patients meeting criteria for AD (n = 1,320), DLB (n = 178), and FTD (n = 348). Cumulative probabilities of developing seizures and myoclonus were compared between diagnostic groups, whereas age-stratified incidence rates were determined relative to control populations. RESULTS: The cumulative probability of developing seizures after disease onset was 11.5% overall, highest in AD (13.4%) and DLB (14.7%) and lowest in FTD (3.0%). The cumulative probability of developing myoclonus was 42.1% overall, highest in DLB (58.1%). The seizure incidence rates, relative to control populations, were nearly 10-fold in AD and DLB, and 6-fold in FTD. Relative seizure rates increased with earlier age-at-onset in AD (age CONCLUSIONS: Seizures and myoclonus occur with greater incidence in patients with AD, DLB, and FTD than in the general population, but rates vary with diagnosis, suggesting varied pathomechanisms of network hyperexcitability. Patients often experience these symptoms early in disease, suggesting hyperexcitability could be an important target for interventions. |
DOI | 10.3233/JAD-170031 |
Alternate Journal | J. Alzheimers Dis. |
PubMed ID | 28826176 |
PubMed Central ID | PMC5608587 |
Grant List | F32 AG050434 / AG / NIA NIH HHS / United States K23 AG038357 / AG / NIA NIH HHS / United States |